ADAG
Adagene Inc.
There isn't enough reported data to score ADAG yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ADAG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ADAG's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ADAG PE Valuation
ADAG has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ADAG Forward outlook
There aren't enough analyst estimates for ADAG to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ADAG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.30 | +$0.46 |
| Q2 2025 | -$0.51 | +$0.39 |
| Q4 2024 | -$0.76 | -$0.22 |
| Q2 2024 | -$0.90 | +$0.16 |
| Q1 2024 | -$0.72 | +$1.64 |
| Q4 2023 | -$0.54 | +$2.45 |
| Q3 2023 | -$0.80 | +$2.74 |
| Q2 2023 | -$1.06 | +$2.52 |
ADAG has the stronger earnings trend. Trailing diluted EPS is down 142% for ADAG versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ADAG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $407.9K | -85% |
| Q3 2023 | $407.9K | -85% |
| Q2 2023 | $8.6M | +120% |
| Q1 2023 | $8.6M | +341% |
| Q4 2022 | $2.7M | -69% |
| Q3 2022 | $2.7M | -39% |
| Q2 2022 | $3.9M | +189% |
| Q1 2022 | $2M | +189% |
ADAG has the stronger quarterly revenue trend. Revenue is up 298% for ADAG versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1024% | N/A |
| Q4 2023 | -2289% | -1621 points |
| Q3 2023 | -2289% | -1621 points |
| Q2 2023 | -29% | +1196 points |
| Q1 2023 | -29% | +1196 points |
| Q4 2022 | -668% | -272 points |
| Q3 2022 | -668% | -272 points |
| Q2 2022 | -1225% | +1535 points |
ADAG's operating margin was −1024% last quarter, down 995 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ADAG on profitability, with a higher operating margin.
ADAG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.9M | -$3.8M |
| Q4 2025 | -$4.5M | +$11.8M |
| Q2 2025 | -$11.1M | -$4.4M |
| Q4 2024 | -$16.3M | -$1.3M |
| Q2 2024 | -$6.7M | +$36K |
| Q1 2024 | -$6.7M | +$36K |
| Q4 2023 | -$15.1M | -196% |
| Q3 2023 | $0 | -100% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with ADAG at down 287%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ADAG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -13.7M shares |
| 1 year | +28% | +10M shares |
| 3 years | +30% | +10.4M shares |
| 5 years | +65% | +17.8M shares |
| Available history | +367% | +35.6M shares |
ADAG has 45M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ADAG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ADAG Net Leverage
ADAG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ADAG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 9.4 | Oversold |
ADAG's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ADAG PE vs Healthcare Sector
ADAG has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ADAG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 18% below |
| 20 week MA | $3.21 | 38% below |
| 50 week MA | $3.15 | 37% below |
| 100 week MA | $2.51 | 20% below |
| 200 week MA | $2.30 | 13% below |
ADAG is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ADAG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $27.7 | $7.50 | -73% |
| 2022 | $7.50 | $1.26 | -83% |
| 2023 | $1.26 | $1.93 | +53% |
| 2024 | $1.93 | $1.96 | +1.6% |
| 2025 | $1.96 | $1.78 | -9.2% |
| 2026 YTD | $1.78 | $2.00 | +12% |
ADAG has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.